Skip to main content

Table 1 Comparisons of baseline characteristics

From: Effects of canagliflozin and metformin on insulin resistance and visceral adipose tissue in people with newly-diagnosed type 2 diabetes

Variables

Active group

(n = 69)

Control group

(n = 73)

Age (years)

57.3 ± 9.8

56.0 ± 8.5

Female, n (%)

33 (47.8)

34 (46.6)

General obesity, n (%)

39 (56.5)

40 (54.8)

Abdominal obesity, n (%)

30 (43.5)

32 (43.8)

Current smoking, n (%)

29 (42.0)

30 (41.1)

Duration of diabetes (months)

5.2 ± 0.6

5.3 ± 0.6

Physical inactivity, n (%)

47 (68.1)

48 (65.8)

Hypertension, n (%)

50 (72.4)

52 (71.2)

Dyslipidemia, n (%)

45 (65.2)

47 (64.4)

Prior CVD history, n (%)

10 (14.5)

8 (11.0)

Aspirin, n (%)

29 (42.0)

29 (39.7)

Statins, n (%)

27 (39.1)

26 (35.6)

Anti-hypertensive medications, n (%)

42 (60.9)

43 (58.9)

  1. CVD cardiovascular disease